You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Claims for Patent: 8,741,847

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,741,847

Title:	Agent and methods for reducing inflammatory markers
Abstract:	A method for treating an autism spectrum condition includes administering an effective dose of a TNF-.alpha. inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-.alpha. in the cerebrospinal fluid or elevated TNF-.alpha. in the serum, as compared to normal conditions; and lowering at least one of the elevated TNF-.alpha. in the cerebrospinal fluid or elevated TNF-.alpha. in the serum. A TNF-.alpha. inhibiting agent includes at least one of Lenalinomide; Thalidomide; L-Carnosine; Infliximab; Etanercept; a stem cell preparation; derivatives thereof, isomers thereof, or pharmaceutically acceptable salts thereof.
Inventor(s):	Chez; Michael (Granite City, CA)
Assignee:
Application Number:	13/463,851
Patent Claims:	1. A method for treating an autism spectrum disorder or pervasive development disorder, comprising: administering an effective dose of a TNF-.alpha. inhibiting agent to a person having an autism spectrum disorder or pervasive development disorder and an elevated ratio of TNF-.alpha. in the cerebrospinal fluid to TNF-.alpha. in serum; and lowering the elevated ratio of TNF-.alpha. in the cerebrospinal fluid to TNF-.alpha. in the serum, wherein the TNF-.alpha. inhibiting agent is selected from the group consisting of lenalinomide; thalidomide; I-carnosine; infliximab; etanercept; and derivatives, isomers, or pharmaceutically acceptable salts of the TNF-.alpha. inhibiting agent. 2. A method according to claim 1 wherein said administering an effective dose of a TNF-.alpha. inhibiting agent to a person having an autism spectrum disorder or pervasive development disorder lowers levels of a proinflammtory cytokine. 3. A method according to claim 2, wherein the proinflammatory cytokine comprises interleukin-1.beta.. 4. A method according to claim 1, wherein the TNF-.alpha. inhibiting agent comprises lenalinomide. 5. A method according to claim 1, wherein the person is a male less than 16 years of age. 6. A method according to claim 1, further comprising administering a corticosteroid to said person. 7. A method according to claim 1, wherein autism spectrum disorder or pervasive development disorder comprises autism or Asperger's. 8. A method according to claim 1, further comprising measuring language skills or social skills of the person. 9. A method for treating an autism spectrum disorder or pervasive development disorder, comprising: administering an effective dose of a TNF-.alpha. inhibiting agent to a patient having an autism spectrum disorder or pervasive development disorder and having an elevated ratio of TNF-.alpha. in the cerebrospinal fluid to TNF-.alpha. in serum; lowering the elevated ratio of TNF-.alpha. in the cerebrospinal fluid to TNF-.alpha. in the serum; and lowering a serum level of a cytokine, wherein the TNF-.alpha. inhibiting agent is selected from the group consisting of lenalinomide; thalidomide; I-carnosine; infliximab; etanercept; and derivatives, isomers, or pharmaceutically acceptable salts of the TNF-.alpha. inhibiting agent. 10. A method according to claim 9, further comprising measuring language skills or social skills of the patient. 11. A method according to claim 9, wherein the cytokine marker comprises Interleuken-1.beta..

Details for Patent 8,741,847

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2029-11-06
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2029-11-06
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2029-11-06
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2029-11-06
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2029-11-06
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017	⤷ Try a Trial	2029-11-06
Immunex Corporation	ENBREL	etanercept	Injection	103795		⤷ Try a Trial	2029-11-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.